The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer-Reference-Cited by-同舟云学术

The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer

Published:2022-10-20 Issue:22 Volume:16 Page:4011-4022
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Molecular Oncology

Author:

Pan Jian¹²³^ORCID,Zhao Jinou¹²³,Ni Xudong¹²³,Gan Hualei²³,Wei Yu¹²³,Wu Junlong¹²³,Zhang Tingwei¹²³,Wang Qifeng²³,Freedland Stephen J.⁴⁵⁶,Wang Beihe¹²³,Song Shaoli³⁷,Ye Dingwei¹²³,Liu Chang³⁷,Zhu Yao¹²³

Affiliation:

1. Department of Urology Fudan University Shanghai Cancer Center China

2. Shanghai Genitourinary Cancer Institute China

3. Department of Oncology, Shanghai Medical College Fudan University Shanghai China

4. Department of Nuclear Medicine Fudan University Shanghai Cancer Center China

5. Department of Surgery, Division of Urology and Samuel Oschin Comprehensive Cancer Institute Cedars‐Sinai Medical Center Los Angeles CA USA

6. Urology Section, Department of Surgery Veterans Affairs Medical Center Durham NC USA

7. Department of Pathology Fudan University Shanghai Cancer Center China

Funder

Chinese Society of Clinical Oncology

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.13320

Reference42 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Metastatic Prostate Cancer

3. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021

4. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

5. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy;BMC Cancer;2024-05-25

2. Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis;Clinical and Translational Oncology;2024-05-15

3. Nomogram to predict the presence of PSMA-negative but FDG-positive lesion in castration-resistant prostate cancer: a multicenter cohort study;Therapeutic Advances in Medical Oncology;2024-01

4. OCT4‑positive circulating tumor cells may predict a poor prognosis in patients with metastatic castration‑resistant prostate cancer treated with abiraterone plus prednisone therapy;Oncology Letters;2023-09-04